Ireland· IE-PA-EU/1/23/1718/001-008
SOTYKTU 6 mg Film-coated tablet
A deucravacitinib product containing deucravacitinib, registered in Ireland by Bristol-Myers Squibb Pharma EEIG.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Deucravacitinib
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Ireland (IE)
- ATC code
- L04AA56
- ATC class
- Deucravacitinib
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1718/001-008
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Deucravacitinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSOTYKTUBristol-Myers Squibb Pharma EEIG, Dublin
- United StatesSOTYKTUE.R. Squibb & Sons, L.L.C.
- FinlandSOTYKTUBristol-Myers Squibb Pharma EEIG
- FranceSOTYKTU 6 mg, comprimé pelliculéBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- BelgiumSotyktu 6 mgBristol-Myers Squibb Pharma
- NetherlandsSOTYKTU 6 mg filmomhulde tablettenBristol-Myers Squibb Pharma EEIG
- NorwaySotyktuBristol-Myers Squibb Pharma EEIG
- PolandSotyktuBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sotyktu
- Liechtenstein · Sotyktu
- Norway · Sotyktu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9a84b22e-fef2-41b0-9232-95d0c9ccded3 GET /v1/drugs/9a84b22e-fef2-41b0-9232-95d0c9ccded3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L04AA",
"L04AA56"
],
"strength": null,
"pa_number": "EU/1/23/1718/001-008",
"substances": [
"Deucravacitinib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "24/03/2023",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about deucravacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.